Moderna, Inc.
NASDAQModerna has delivered one of its strongest weekly performances of the year, up 16% to $55.40, yet short sellers have barely flinched — and that contradiction is the story this week. Short interest is elevated and sticky. At nearly 15% of free float, it remains one of the higher readings in the biotech space, and the weekly change has been essentially flat — up just 1.3% despite the…
Snapshot as of 22 Jun 2026
Moderna has delivered one of its strongest weekly performances of the year, up 16% to $55.40, yet short sellers have barely flinched — and that contradiction is the story this week. Short interest is elevated and…
Moderna heads into Wednesday's first-quarter release with analysts freshly raising targets — yet none willing to turn bullish. The most striking feature of the run-up is the breadth and speed of analyst target upgrades…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRNA — free to start on ORTEX.
Sign up for free →Open MRNA on ORTEX